Press release
August 12, 2026
Spruce Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
Spruce Biosciences, Inc. (SPRB)
Biologics License Application (BLA) for TA-ERT for the Treatment of MPS IIIB Anticipated in the Fourth Quarter of 2026 TrAnsform Confirmatory Study Required for Potential FDA Accelerated Approval of TA-ERT Expected to Initiate in the Fourth Quarter of 2026 Strengthened Leadership Team with the